SI20744B - Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje - Google Patents

Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje Download PDF

Info

Publication number
SI20744B
SI20744B SI200020021A SI200020021A SI20744B SI 20744 B SI20744 B SI 20744B SI 200020021 A SI200020021 A SI 200020021A SI 200020021 A SI200020021 A SI 200020021A SI 20744 B SI20744 B SI 20744B
Authority
SI
Slovenia
Prior art keywords
amino
methyl
oxo
dihydro
carbonyl
Prior art date
Application number
SI200020021A
Other languages
English (en)
Other versions
SI20744A (sl
Inventor
Ronald J Biediger
Qi Chen
George W Holland
Jamal M Kassir
Wen Li
Robert V Market
Ian L Scott
Chengde Wu
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of SI20744A publication Critical patent/SI20744A/sl
Publication of SI20744B publication Critical patent/SI20744B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Postopek za inhibiranje vezave alfa4beta1 integrira na njegove receptorje, npr. VCAM-1 (vaskularna celična adhezijska molekula-1) in fibronektin; spojine, ki inhibirajo to vezavo; farmacevtsko aktivni sestavki, ki obsegajo take spojine, in uporaba takih spojin bodisi kot zgoraj ali v pripravkih za kontrolo ali preprečevanje bolezenskih stanj, v katera je vpleten alfa4beta1.

Claims (7)

1 SI 20744 - UO Patentni zahtevki
ali njena farmacevtsko sprejemljiva sol, kjer Y pri vsakem pojavljanju neodvisno izberemo iz skupine, ki obstoji iz naslednjih, kot so C (O), N, CR1, C (R2) (R3) in CH; in je obroč, ki vsebuje Y, lahko po izbiri bicikličen obroč; q je celo število od 2 do 5; B in R6 neodvisno izberemo iz skupine, katero sestavljata vodik in alkil, R1 pri vsakem pojavljanju neodvisno izberemo iz skupine, katero sestavljajo: vodik, halogen, hidroksilna, alkilna, alkenilna, alkinilna, alkoksi, alkenoksi, alkinoksi, tioalkoksi, hidroksialkilna, alkil-C(O)-, alkenil-C(O)-, alkinil-C(O)-, -CF3, nitro, amino, ciano, karboksi, -N(Ci-C3alkil)-C(0)(Ci-C3alkilna), -NHC(0)N(CrC3alkil)C(0)NH(Ci-C3alkilna), -NHC(0)NH(CrC6alkilna), alkilamino, alkenilamino, di(Ci-C3)amino, -C(0)0-(CrC3)alkilna, -C(0)NH-(CrC3)alkilna, -C(0)N(CrC3alkilna)2, -CH=NOH, -P03H2, -0P03H2, haloalkilna, alkoksialkoksi, karboksaldehidna, karboksamidna, cikloalkilna, cikloalkenilna, cikloalkilalkilna, arilna, aroilna, ariloksi, arilamino, biarilna, tioarilna, diarilamino, heterociklilna, alkilarilna, aralkenilna, aralkilna, alkilheterociklilna, heterociklilalkilna, sulfonilna, -S02(CrC3alkilna), -S03(CrC3alkilna), sulfonamido, karbamatna, ariloksialkilna, karboksilna in -C(0)NH(benzilna) skupina, kjer je vsak R1 lahko nesubstituiran ali substituiran z enim ali večimi 2 SI 20744 - UO substituenti, izbranimi iz skupine, katero sestavljajo aril, Ci-C6alkoksi, alkoksialkoksi in alkil; in kjer, kadar je vsaj en Y CR1, lahko R1 in R6 skupaj tvorita obroč; R inR sta, kadar sta prisotna, vodik; R4 izberemo iz skupine, katero sestavljata alkil in aril; R5 izberemo iz skupine, katero sestavljajo aralkil, ariloksialkil in cikloalkilalkil; R je vodik; R9 in R10 izberemo iz skupine, katero sestavljata vodik in halogen; in kjer, v kolikor ni drugače navedeno, alkil, sam ali v kombinaciji, se nanaša na CpCu ravne ali razvejene nasičene verižne radikale izvedene iz nasičenih ogljikovodikov z odstranitvijo enega vodikovega atoma; alkenil, sam ali v kombinaciji, se nanaša na raven ali razvejen alkenilni radikal, ki vsebuje od 2 do 10 ogljikovih atomov; alkinil, sam ali v kombinaciji, se nanaša na raven ali razvejen alkenilni radikal, ki vsebuje od 2 do 10 ogljikovih atomov; cikloalkil se nanaša na alifatski obročni sistem, ki ima 3 do 10 ogljikovih atomov in 1 do 3 obroče, ki so lahko po izbiri substituirani z enim, dvema ali tremi substituenti, neodvisno izbranimi izmed Ci-C6alkila, haloalkila, alkoksi, tioalkoksi, amino, alkilamino, dialkilamino, hidroksi, halo, merkapto, nitro, karboksaldehida, karboksi, alkoksikarbonila in karboksamida; cikloalkenil, sam ali v kombinaciji, se nanaša na cikličen karbocikel, ki vsebuje od 4 do 8 ogljikovih atomov in eno ali več dvojnih vezi; cikloalkilalkil se nanaša na cikloalkilno skupino, pripeto na Ci-C6alkilni radikal; haloalkil se nanaša na CrC6 alkilni radikal, na katerega je pripet vsaj en halogenski substituent; alkoksi, sam ali v kombinaciji, se nanaša na alkiletrski radikal, kjer je alkil kot je definirano zgoraj; alkenoksi se nanaša na radikal s formulo alkenil-O, pod pogojem, da radikal ni enolni eter, kjer je alkenil kot je definirano zgoraj; 3 SI 20744 UO alkinoksi se nanaša na radikal s formulo alkinil-O, pod pogojem, da radikal ni-inolni eter, tioalkoksi se nanaša na tioetrski radikal s formulo alkil-S-, kjer je alkil, kot je definirano zgoraj; alkoksialkoksi se nanaša na Rg-Rh O-, kjer je Rg Ci-C6 alkil in je Rh -(CH2)n-, kjer je n' celo število od 1 do 6; alkilamino se nanaša na RjNH-, kjer je Rj CpCgalkilna skupina, pod pogojem, da radikal ni enamin; alkenilamino se nanaša na radikal s formulo, alkenil-NH-ali (alkenil)2N-, kjer je alkenil, kot je definirano zgoraj, pod pogojem, da radikal ni enamin; dialkilamino se nanaša na RjRkN-, kjer sta R, in Rk neodvisno izbrana izmed Ci.Cealkila; aril, sam ali v kombinaciji, se nanaša na karbociklično aromatsko skupino, ki ima od 6 do 12 ogljikovih atomov ali heterociklično aromatsko skupino, ki vsebuje vsaj en endocikličen N, O ali S atom, pri čemer je naveden aril po izbiri substituiran z vsaj eno skupino, izbrano iz skupine, katero sestavljajo alkoholi, etri, estri, amidi, sulfoni, sulfidi, hidroksil, nitro, ciano, karboksi, amini, heteroatomi, Ci-C6alkil, Ci-C6alkoksi, Ci-C6-alkoksi-CO-, alkoksialkoksi, aciloksi, halogeni, trifluorometoksi, trifluorometil, alkil, aralkil, alkenil, alkinil, aril, ciano, karboksi, karboalkoksi, karboksialkil, cikloalkil, cikloalkilalkil, heterociklil, alkilheterociklil, heterociklilalkil, okso, arilsulfonil in aralkilaminokarbonil, kjer so navedeni substituenti po izbiri vezani s pomočjo linkeija, izbranega izmed verige z 1-3 atomi, ki vsebuje katero koli kombinacijo od -C-, -C(O)-, -NH-, -S-, -S(O)-, -0-, -C(0)0-; tioaril se nanaša na radikal s formulo aril-S-, kjer je aril kot je definirano zgoraj; se heterociklil, sam ali v kombinaciji, nanaša na nearomatski 3-7 členski obroč, ki vsebuje vsaj en endocikličen, N, O ali S atom, pri čemer je naveden heterociklil, po izbiri arilno-pripojen in po izbiri substituiran z vsaj enim substituentom, neodvisno izbranim iz skupine, katero sestavljajo vodik, halogen, hidroksil, amino, nitro, trifluorometil, trifluorometoksi, alkil, aralkil, alkenil, alkinil, aril, ciano, karboksi, karboalkoksi, karboksialkil, okso, arilsulfonil in aralkilaminkarbonil. 4 Sl 20744 - UO
2. Spojina po zahtevku 1, kjer 4 Sl 20744 - UO
je izbrana iz skupine, katero sestavljajo
kjer R18, R19, R20 in R21 pri vsakem pojavljanju neodvisno izberemo skupine, katero sestavljajo vodik, halogen, hidroksil, alkil, alkenil, alkinil, alkoksi, alkenoksi, alkinoksi, tioalkoksi, hidroksialkil, alifatski acil, -CF3, nitro, amino, ciano, karboksi, -N(C1-C3alkil)-C(0)(C1-C3alkil), -NHC(0)N(CrC3 alkil)C(0)NH(C,-C3alkil), -NHC(0)NH(Ci-C6alkil), alkilamino, alkenilamino, di(Ci-C3)amino, -C(0)0-(C,-C3)alkil, -C(0)NH-(CrC3)alkil, -C(0)N(C,-C3 alkil)2, -CH=NOH, -P03H2, -0P03H2, haloalkil, alkoksialkoksi, karboksaldehid, karboksamid, cikloalkil, cikloalkenil, cikloalkinil, cikloalkilalkil, aril, aroil, ariloksi, arilamino, biaril, tioaril, diarilamino, heterociklil, alkilaril, aralkenil, aralkil, alkilheterociklil, heterociklilalkil, sulfonil, -S02-(Ci-C3 alkil), -S03-(Ci-C3 alkil), sulfonamido, karbamat, ariloksialkil, karboksil in -C(0)NH(benzilne) skupine; c je celo število nič do dva; d je celo število nič do tri; e je celo število nič do štiri in f je celo število nič do ena. 5 SI 20744 - UO
3. Spojina po zahtevku 1, kjer je R5 arilalkil; je R4 aril in sta B in R6 vsak neodvisno vodik. 1 n e
4. Spojina po zahtevku 1, kjer sta dve neodvisni R , R , R ali R skupini lahko povezani skupaj, da tvorita obroč.
5. Spojina po zahtevku 1, izbrana iz skupine, katero sestavljajo: (3 S)-3-[( {[2-metil-4-(2-metilpropil)-6-okso-1 -(fenilmetil)-1,6-dihidro-5-pirimidinil]amino}karbonil)amino]-3-(4-metilfenil)propanojska kislina; (3 S)-3 -(1,3 -benzodioksol-5-il)-3 - [({[2-okso-1 -(fenilmetil)-4-propil-1,2-dihidro-3 -piridinil] amino} karbonil)amino]propanoj ska kislina; (3 S)-3 - {[({1 - [(2-klorofenil)metil]-4-etil-2-okso-1,2-dihidro-3-piridinil} aminojkarbonil] amino} -3-(4-metilfenil)propanojska kislina; (3 S)-3- {[( {1 -[(2-klorofenil)metil]-2-okso-4-propil-1,2-dihidro-3-piridinil} aminojkarbonilj amino} -3-(4-metilfenil)propanojska kislina; (3 S)-3- {[({1 -[(2-klorofenil)metil]-4-metil-2-okso-1,2-dihidro-3-piridinil}amino)karbonil]amino}-3-(4-metilfenil)propanojska kislina; (3S)-3- {[({6-metil-2-okso-1 -(fenilmetil)-4-[(fenilmetil)oksi]-1,2- dihidro-3-piridinil} amino)karbonil] amino} -3-(4-metilfenil)propanojska kislina; (3S)-3-{[({l-[(2-klorofenil)metil]-2,4-dimetil-6-okso-l,6-dihidro-5-pirimidinil} aminojkarbonil] amino} -3-(4-metilfenil)propanojska kislina; (3S)-3- {[({4-amino-1 -[(2-klorofenil)metil]-6-metil-2-okso-1,2-dihidro-3- 6 Si 20744 - UO piridinil} amino)karbonil] amino} -3 -(4-metilfenil)propanoj ska kislina; (3 S)-3- {[({1 -[(2-klorofenil)metil]-4-metil-2-okso-1,2-dihidro-3-piridinil} amino)karbonil]amino} -3-(4-metiloksi)fenil]propanojska kislina; (3S)-3-{[({l-[(2-klorofenil)metil]-4-metil-2-okso-l,2-dihidro-3-piridinil}amino)karbonil]amino}-3-(3,4-dimetilfenil)propanojska kislina; (3 S)-3-{[( {4-amino-1 - [(2-klorofenil)metil]-2-okso-1,2-dihidro-3-piridinil} amino)karbonil] amino} -3-(4-metilfenil)propanojska kislina; (3S)-3- {[({1 -[(2-klorofenil)metil]-4-hidroksi-2-okso-1,2-dihidro-3-piridinil} amino)karbonil] amino } -3 -(4-metilfenil)propanoj ska kislina; (3S)-3-[( {[1 -[(2-klorofenil)metil]-4-( 1,4-oksazinan-4-il) -2-okso-1,2-dihidro-3-piridinil]-amino}karbonil)amino]-3-(4-metilfenil)propanojska kislina; (3 S)-3- [({[ 1 -[(2-klorofenil)metil]-2-okso-4-(propilamino)-1,2-dihidro-3-piridinil]-amino}karbonil)amino]-3-(4-metilfenil)propanojska kislina; (3S)-3- {[( {1 -[(2-bromofenil)metil]-4-metil-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil] amino} -3 -(4-metilfenil)propanoj ska kislina; (3S)-3- {[({1 -[(2-klorofenil)metil]-4-hidroksi-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil] amino } - 3 - [ 3 -metil-4-(metiloksi)fenil]propanoj ska kislina; (3S)-3- {[({1 -[(2-klorofenil)metil]-2-okso-4-fenil-1,2-dihidro-3-piridinil} -amino)karbonil]amino} -3-[4-metilfenil)propanoj ska kislina; 7 Sl 20744 UO (3S)-3- {[({l-[(2-klorofenil)metil]-4-[(2- {[2-(metiloksi)etil]oksi} etil)oksi]-2-okso-1,2-dihidro-3-piridinil}-amino)karbonil]amino}-3-(4-metilfenil)propanojska kislina; (3 S)-3- {[({1 -[(2-klorofenil)metil]-4-hidroksi-9-metil-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil]amino} -3-(4-metilfenil)propanojska kislina; (3 S)-3- {[({1 -[(2-klorofenil)metil]-4-[( 1,1 -dimetiletil)amino-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil]amino} -3-(4-metilfenil)propanojska kislina; (3 S)-3 - {[({1 - [(2-klorofenil)metil] -4-hidroksi-2-okso-1,2-dihidro-3 -piridinil}-amino)karbonil]amino}-3-fenilpropanojska kislina; (3S)-3-{[({l-[(2-klorofenil)metil]-4-[4-metiltetrahidro-l(2H)-pirazinil]-2- okso-l,2-dihidro-3-piridinil}-amino)karbonil]amino}-3-(4-metilfenil)propanojska kislina; (3S)-3- {[( {1 -[(2-klorofenil)metil]-4- hidroksi-2-okso-1,2-dihidro-3-piridinil}-amino)karbonil]amino}-3-[4-metiloksi)fenilpropanojska kislina; (3 S)-3- {[({1 -[(2-klorofenil)metil]-4- hidroksi-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil]amino} -3-(3,5-dimetilfenil)propanojska kislina; (3S)-3- {[({l-[(2-klorofenil)metil]-4- hidroksi-2-okso-l ,2-dihidro-3-piridinil}-amino)karbonil]amino}-3-(3-metilfenil)propanojska kislina; (3S)-3- {[( {1 -[(2-klorofenil)metil]-4- hidroksi-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil]amino} -3-(3-metiloksi)fenil]propanojska kislina; (3S)-3-[3,5-bis(metiloksi)fenil]-3-{[({l-[(2-klorofenil)metil]-4-hidroksi-2-okso-1,2-dihidro-3 -piridinil} amino)karbonil] amino} propanoj ska kislina; 8 SI 20744 - UO (3S)-3- {[( {1 -[(2-klorofenil)metil]-4-hidroksi-2-okso-1,2-dihidro-3-kinolinil} -amino)karbonil]amino} -3-(4-metilfenil)propanojska kislina; (3S)-3- {[({1 -[(2-klorofenil)metil]-4-hidroksi-2-okso-1,2-dihidro-3-piridinil}-amino)karbonil]amino}-3-[3-(trifluorometil)fenil]propanojska kislina; (3 S)-3- {[({1 -[(2-klorofenil)metil]-4- [({etil[(etilamino)karbonil]amino} karbonil)amino]-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil]amino} -3-[4-metilfenil)propanojska kislina; (3 S)-3- {[({4-( 1 -azetanil)-1 -[(2-klorofenil)metil]-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil]amino} -3-[4-metilfenil)propanojska kislina; (3S)-3-[({[l-[(2-klorofenil)metil]-4-}2-[(2-{[2-(metiloksi)etil]oksi} etil)oksi]etil} oksi)-2-okso-1,2-dihidro-3-piridinil] -amino} karbonil)amino]-3 -(4-metilfenil)propanoj ska kislina; (3 S)-3- {[({1 [(2-fluorofenil)metil]-4-hidroksi-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil] amino} -3-[4-metilfenil)propanojska kislina; (3 S)-3- {[({1 [(2-kloro-6-fluorofenil)metil]-4-hidroksi-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil] amino} -3-[4-metilfenil)propanojska kislina; (3 S)-3- {[({1 [(2-klorofenil)metil]-5-metil-2-okso-1,2-dihidro-3-piridinil} -amino)karbonil] amino} -3-[4-metilfenil)propanojska kislina; (3S)-3-(l,3-benzodioksol-5-il)-3-((((2-okso-l-((4-trifluorometil)fenil)metil)-l,2-dihidro-3-piridinil)amino)karbonil)amino)propanojska kislina; (3S)-3-((((l-((2-klorofenil)metil)-2-okso-l,2-dihidro-3-piridinil)amino)karbonil)amino)-3-(4-metilfenil)propanojska kislina; 9 SI 20744 - UO (3 S)-3-((((1-((2-fluorofenil)metil)-2-okso-l,2-dihidro-3-piridinil)amino)karbonil)amino)-3 -(4-metilfenil)propanoj ska kislina; (3 S)-3-(((( 1 -((2-bromofenil)metil)-2-okso-1,2-dihidro-3-piridinil)amino)karbonil)amino)-3-(4-metilfenil)propanojska kislina; (3S)-3-((((l-((2,4-diklorofenil)metil)-2-okso-l,2-dihidro-3-piridinil)amino)karbonil)amino)-3-(4-metilfenil)propanojska kislina; (3S)-3-((((l-((2-kloro-6-fluorofenil)metil)-2-okso-l,2-dihidro-3-piridinil)amino)karbonil)amino)-3 -(4-metilfenil)propanoj ska kislina; (3 S)-3-(((( 1 -((2-klorofenil)metil)-4-hidroksi-2-okso-1,2-dihidro-3-piridinil)amino)karbonil)amino)-3-(4-trifluorometil)oksi)fenil)propanojska kislina; in njihove farmacevtsko sprejemljive soli.
6. Farmacevtski sestavek, ki obsega spojino po zahtevku 1 v farmacevtsko sprejemljivem nosilcu.
7. Uporaba spojine po zahtevku 1 za izdelavo zdravila za selektivno inhibiranje (Χ4βι integrinske vezave pri sesalcu, kjer naj se njena terapevtska količina daje navedenemu sesalcu.
SI200020021A 1999-05-07 2000-05-05 Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje SI20744B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13297199P 1999-05-07 1999-05-07
PCT/US2000/012303 WO2000067746A1 (en) 1999-05-07 2000-05-05 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Publications (2)

Publication Number Publication Date
SI20744A SI20744A (sl) 2002-06-30
SI20744B true SI20744B (sl) 2009-08-31

Family

ID=22456441

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200020021A SI20744B (sl) 1999-05-07 2000-05-05 Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje

Country Status (23)

Country Link
EP (1) EP1176956B1 (sl)
JP (1) JP5132855B2 (sl)
AT (1) ATE383153T1 (sl)
AU (1) AU5267900A (sl)
CA (1) CA2373360C (sl)
CY (1) CY1107438T1 (sl)
CZ (1) CZ303312B6 (sl)
DE (1) DE60037726T2 (sl)
DK (1) DK1176956T3 (sl)
ES (1) ES2296625T3 (sl)
IL (2) IL146311A0 (sl)
IN (1) IN2001KN01110A (sl)
MX (1) MXPA01011340A (sl)
NO (1) NO324421B1 (sl)
NZ (1) NZ515248A (sl)
PL (1) PL205322B1 (sl)
RO (1) RO122246B1 (sl)
RU (1) RU2263109C2 (sl)
SI (1) SI20744B (sl)
SK (1) SK286696B6 (sl)
TR (2) TR200103178T2 (sl)
WO (1) WO2000067746A1 (sl)
ZA (1) ZA200108774B (sl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
JP4616643B2 (ja) 2002-06-28 2011-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの用途
CN1703395A (zh) 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
TW200505861A (en) * 2002-11-08 2005-02-16 Encysive Pharmaceuticals Inc Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
EP1581501A1 (en) 2002-12-20 2005-10-05 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
US8410150B2 (en) 2007-03-09 2013-04-02 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
CA2677049A1 (en) 2007-08-01 2009-02-05 Sionex Corporation Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
MX2011011326A (es) * 2009-04-27 2012-02-13 Elan Pharm Inc Antagonistas de piridinona de las integrinas alfa-4.
WO2012033548A2 (en) * 2010-09-07 2012-03-15 E. I. Du Pont De Nemours And Company Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles
CA2771588C (en) 2009-09-09 2018-07-31 E I Du Pont De Nemours And Company Herbicidal pyrimidone derivatives
EP2810937B1 (en) * 2012-01-31 2016-11-30 Daiichi Sankyo Company, Limited Pyridone derivative
TWI690511B (zh) 2013-09-20 2020-04-11 美商拜奧馬林製藥公司 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑
JP2017510627A (ja) 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
CN106459042B (zh) * 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
US10246451B2 (en) * 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
MX2019012699A (es) * 2017-04-28 2020-12-11 Texas Childrens Hospital Nanoparticulas dirigidas.
KR20260007293A (ko) * 2018-02-02 2026-01-13 제넨테크, 인크. 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614189A1 (de) * 1976-04-02 1977-10-20 Hoechst Ag Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
DE69425431T2 (de) * 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
AU672699B2 (en) * 1993-06-30 1996-10-10 Sankyo Company Limited Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
PT912901E (pt) * 1996-05-15 2002-04-29 Searle & Co Metedo e reagentes para monitorizacao dos niveis sanguineos de compostos antiagregantes plaquetares
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
HK1040076A1 (zh) * 1998-09-21 2002-05-24 希雷生物化学有限公司 作为整联蛋白抑制剂的喹嗪酮

Also Published As

Publication number Publication date
IL146311A0 (en) 2002-07-25
TR200103178T2 (tr) 2002-05-21
WO2000067746A1 (en) 2000-11-16
CY1107438T1 (el) 2012-12-19
ATE383153T1 (de) 2008-01-15
JP5132855B2 (ja) 2013-01-30
AU5267900A (en) 2000-11-21
CA2373360C (en) 2011-09-06
NO324421B1 (no) 2007-10-08
SK16082001A3 (sk) 2002-04-04
MXPA01011340A (es) 2003-08-01
HK1045805A1 (en) 2002-12-13
CZ303312B6 (cs) 2012-07-25
NZ515248A (en) 2004-01-30
NO20015418D0 (no) 2001-11-06
NO20015418L (no) 2001-12-21
EP1176956A4 (en) 2002-08-28
CA2373360A1 (en) 2000-11-16
ZA200108774B (en) 2003-01-24
SK286696B6 (sk) 2009-03-05
CZ20013963A3 (cs) 2002-04-17
ES2296625T3 (es) 2008-05-01
RO122246B1 (ro) 2009-03-30
DK1176956T3 (da) 2008-05-26
DE60037726D1 (de) 2008-02-21
RU2263109C2 (ru) 2005-10-27
PL351396A1 (en) 2003-04-07
SI20744A (sl) 2002-06-30
WO2000067746A9 (en) 2002-08-29
DE60037726T2 (de) 2009-03-05
TR200201920T2 (tr) 2002-09-23
WO2000067746A8 (en) 2002-02-28
IL146311A (en) 2011-10-31
JP2002544161A (ja) 2002-12-24
IN2001KN01110A (sl) 2015-06-05
EP1176956B1 (en) 2008-01-09
EP1176956A1 (en) 2002-02-06
PL205322B1 (pl) 2010-04-30

Similar Documents

Publication Publication Date Title
SI20744B (sl) Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje
RU2004110725A (ru) Гетероциклические производные арилзамещенных пиридинов, использование их в качестве блокаторов натриевых каналов, фармацевтическая композиция
RU2483072C2 (ru) Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
RU97105769A (ru) Гетероциклическое производное и лекарственное средство
AR029489A1 (es) Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2328990A1 (en) N,n-disubstituted amides that inhibit the binding of integrins to their receptors
HUP0302969A2 (hu) NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
KR970705545A (ko) 복소환 유도체 및 의약(heterocyclic derivative and medicine)
KR920002560A (ko) 살균제
DK1119567T3 (da) Quinazolinderivater
CA2369560A1 (en) Agent for prophylaxis and treatment of liver disease
RU2001112421A (ru) Бензоилциклогександионы, способ их получения и их применение в качестве гербицидов и регуляторов роста растений
ES2141137T3 (es) Agentes terapeuticos para la enfermedad de parkinson.
KR970704444A (ko) 트리아진 유도체 및 의약(triazine derivative and medicine)
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
RU97103983A (ru) Лекарственные композиции и производные триазина
RU2005111590A (ru) 2,4-замещенные индолы и их использование в качестве модуляторов 5-гт6
FR2586679B1 (fr) Composes heterocycliques, procedes pour leur preparation, et compositions pharmaceutiques les contenant pour inhiber l'enzyme de conversion de l'angiotensine
RU2004129725A (ru) Новое производное ариламидина или его соль
EP1553096A4 (en) pyrazole
EP1750703A4 (en) METHOD FOR REDUCING GASTROINTESTINAL TOXICITY BY ADMINISTRATION OF TEGAFUR
FR2803593B1 (fr) Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
BRPI0409088A (pt) composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
EP0309425A3 (en) New heterocyclic derivatives
KR930021638A (ko) 이미다조피리딘

Legal Events

Date Code Title Description
IF Valid on the event date
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20090521

SP73 Change of data on owner

Owner name: ENCYSIVE PHARMACEUTICALS, INC.; US

Effective date: 20100216

KO00 Lapse of patent

Effective date: 20170216